BerGenBio Reports First Quarter 2023 Financial Results and Provides Business Update
Bergen, Norway, June 22, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the first quarter ended March 31, 2023, and provided a business update. “We recently reported the positive readout of several clinical trials that strongly validate our strategy to concentrate our efforts on evaluating bemcentinib to treat Non-Small Cell Lung Cancer patients harboring STK11 mutations,” said Martin Olin, Chief Executive Officer of BerGenBio. “I